Amendment to the Claims:

1. (Original) A composition comprising Nogo and Caspr, or mimetics thereof, or a substance capable of promoting interaction between Nogo and Caspr, in combination with a carrier.

2. (Original) A composition according to claim 1 wherein the composition comprises a complex between Nogo and Caspr, or a mimetic of said complex.

3. (Currently amended) A composition according to claim 1 ~~or claim 2~~ comprising Nogo-66.

4. (Currently amended) A composition according to ~~any one of~~ claim~~s~~ 1 ~~to 3~~ comprising Caspr1.

5. (Original) A composition according to claim 1 wherein the substance capable of promoting interaction between Nogo and Caspr is an antibody.

6. (Original) A composition according to claim 5 wherein the antibody is capable of binding to both Nogo and Caspr.

7. (Currently amended) A composition according to ~~any one of~~ claim~~s~~ 1 ~~to 6~~, which is a pharmaceutical composition.

8. (Original) A pharmaceutical composition according to claim 7 which is formulated for injection in vivo.

9. (Original) A pharmaceutical composition according to claim 8 which is formulated for direct injection into the CNS.

10.-15. (Canceled)

16. (Currently amended) A method of stimulating myelination of a neural axon, comprising contacting a neuron or an oligodendroglial cell with a composition according to ~~any one of~~ claim~~s~~ 1 ~~to 9~~.

17. (Currently amended) A method of treating a subject having disease of, or injury to, the central nervous system, comprising administering to the subject a pharmaceutical composition according to ~~any one of~~ claim~~s~~ 7 ~~to 9~~.

18. (Original) A method according to claim 17 wherein the subject has SCI, MS, epilepsy or stroke.

19. (Original) A method of screening for a substance capable of modulating interaction between Nogo and Caspr, the method comprising contacting Nogo, Caspr and a candidate substance, and determining the interaction between Nogo and Caspr.

20. (Original) A method according to claim 19 further comprising contacting Nogo and Caspr in the absence of said candidate substance under otherwise analogous conditions, and determining the interaction between Nogo and Caspr.

21. (Currently amended) A method according to claim 19 ~~or claim 20~~ comprising contacting a complex between Nogo and Caspr with the candidate substance.

22. (Currently amended) A method according to ~~any one of~~ claim~~s~~ 19 ~~to 21~~ wherein one of Nogo and Caspr is present in or on a cell.

23. (Original) A method according to claim 22 wherein said one of Nogo and Caspr is expressed from a vector introduced into said cell.

24. (Currently amended) A method according to ~~any one of~~ claim~~s~~ 19 ~~to 23~~ wherein one of Nogo and Caspr is immobilised on a solid support.

25. (Currently amended) A method of manufacturing a pharmaceutical formulation comprising, having identified a substance capable of modulating interaction between Nogo and Caspr by a method according to ~~any one of~~ claim~~s~~ 19 ~~to 24~~, the further step of formulating said substance with a pharmaceutically acceptable carrier.

26. (Original) A method according to claim 25 comprising the further step of optimising said substance for administration in vivo.

27.-62. (Canceled)